Naloxone Oral Syringes
Cancelled on SAM.gov (notice posted October 27, 2025). Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 3:00 PM MDT
- Posted
- October 27, 2025
- Notice type
- Solicitation
- Set-aside
- No Set aside used
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of WarDepartment of the Army
Notice details
- Office
- US ARMY MEDICAL COMMAND.W40M MRC0 WEST
- Place of performance
- JBSA Ft Sam Houston, Texas, 78234
- Last updated
- Nov 8, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- W81K00-26-Q-A022
- Notice ID
- 0e2f545a1b5f41118bf8587aa5d5e61f
Description
THE PURPOSE OF SOLICITATION AMENDMENT 0002 IS TO EXTEND THE SOLICITATION TO 28 OCTOBER 2025 FOR THE NALOXONE 2MG/2ML ORAL SYRINGES.
The Department of Pharmacy at Brooke Army Medical Center (BAMC) is requesting a base plus 4 year (5 years total) contract for 1,413 Naloxone oral syringes annually.
Bidder Questions Due: 17 Oct 2025
Responses Due: 28 Oct 2025, 3:00 p.m., MST
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Files (5)
- Download
Solicitation Amendment - W81K0026QA0220001.pdf
2.6 MBAdded in Solicitation version 4Posted - Download
Combined Synopsis Solicitation.docx
20 KBAdded in Solicitation version 4Posted - Download
Brand Name Justification (Naloxone Oral Syringes) KO Signed._Redacted.pdf
516 KBAdded in Solicitation version 4Posted - Download
Solicitation Amendment - W81K0026QA0220002.pdf
2.6 MBAdded in Solicitation version 4Posted - Download
Questions and Answers_10SEPT25_Redacted.pdf
884 KBAdded in Solicitation version 4Posted
Lifecycle
- 3Version 3Sources SoughtArchived
Naloxone Oral Syringes
- 4Version 4SolicitationArchived
Type changed from Sources Sought to Solicitation
Naloxone Oral Syringes
- 5Version 5SolicitationCancelledArchivedCurrent
Naloxone Oral Syringes
Other notices for this solicitation
- Combined SynopsisRelated noticeSep 24, 2025
Naloxone Oral Syringes
- Combined SynopsisRelated noticeOct 27, 2025
Naloxone Oral Syringes
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Request for Quote (RFQ): The Tennessee Army National Guard (TNARNG) Purchasing and Contracting Office for United States Property and Fiscal Office (USPFO) TN located at 3041 Sidco Drive, Nashville, TN 37204is issuing an RFQ for commercial single award contract in accordance with (IAW) the format in Federal Acquisition Regulations (FAR) subpart 12 as supplemented with additional information included in this notice. The North American Industry Classification System (NAICS)code for this requirement is 325412 Pharmaceutical Preparation Manufacturing. This documentation incorporates provisions and clauses that are in effect through the Federal Acquisition Circular (FAC) 2026-06 effective date 03/13/2026. The Government intends to award a single Firm Fixed Price contract. PLEASE SEE ATTACHED SOLICITATION FOR MORE INFORMATION. | 66% | Combined Synopsis | 04/23/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | 64% | Solicitation | 11/30/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed: a. Ophthalmic - Dry Eye Cequa Eysuvis Miebo Tryptyr Tyrvaya Verkazia Vevye Xiidra b. Testosterone Replacement Therapy - Orals Jatenzo Kyzatrex Tlando The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. | 64% | Solicitation | 12/07/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | 64% | Solicitation | 10/26/2026 |
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Awiqli Flextouch - Insulin - Basal b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors c. Lipfendra - Antilipidemics-1 - PCSK-9 d. Trutakna - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2. | 64% | Solicitation | 08/27/2026 |
Additional Details
Solicitation Number
W81K00-26-Q-A022
Archive Date
Nov 12, 2025
Office Address
JBSA FT SAM HOUSTON, TX, 78234-4504